New Henry Ford Health study about Hydroxychloroquine lowering death rate by 50% compared with other drugs ‘makes remdesivir irrelevant,’ Cardiologist Dr. Ramin Oskoui says

For those of you who have been following us for the past four months, you know we’ve written many articles to get the real truth about hydroxychloroquine, the cheap anti-malaria drug that many doctors claimed to have saved their coronavirus patients’ lives. For months, we’ve been accused of having financial interest in drug, which of course, is absurd. Again, to set the record straight, we have zero investment in any pharmaceutical company.

That being said, the reason we’ve been covering hydroxychloroquine is simply because of questions surrounding the media coverage of the drug and how our public health officials like Dr. Fauci, big pharmaceutical companies, and mainstream media rejected the drug without waiting for the results of randomized test trials. The questions we have are: Why is everyone opposed to a drug that has been in use for almost half a decade? Why are our top health officials, big pharma and mainstream media pushing Gilead’s remdesivir even though study shows it only helped those on oxygen?

On Monday, we wrote about how pharmaceutical companies looked to cash in from coronavirus crisis as Gilead says its COVID-19 treatment drug remdesivir will cost $3,120 per U.S. patient. Now, a new bombshell study conducted by Henry Ford Health System in Detroit found that hydroxychloroquine significantly cut death rate in COVID-19 patients.

So the question is, where does that leave us with Gilead’s remdesivir? Cardiologist Dr. Ramin Oskoui, CEO of Foxhall Cardiology, said the results of the latest hydroxychloroquine study “makes remdesivir irrelevant.”

Below is a video of Dr. Ramin and his analysis of remdesivir.

New Henry Ford Health study about Hydroxychloroquine lowering death rate by 50% compared with other drugs https://t.co/ZYCNpozuXU

— thetechstartups (@thetechstartups) July 3, 2020